129 related articles for article (PubMed ID: 38467640)
1. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
[TBL] [Abstract][Full Text] [Related]
2. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
[TBL] [Abstract][Full Text] [Related]
3. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.
Hao Y; Wang J; Ma J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
Bioorg Chem; 2023 Aug; 137():106584. PubMed ID: 37163814
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
8. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
9. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
[TBL] [Abstract][Full Text] [Related]
10. IRAK4 exacerbates traumatic brain injury via activation of TAK1 signaling pathway.
Xu X; Zhi T; Hua L; Jiang K; Chen C
Exp Neurol; 2022 May; 351():114007. PubMed ID: 35149117
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
[TBL] [Abstract][Full Text] [Related]
13. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
[TBL] [Abstract][Full Text] [Related]
14. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.
De Nardo D; Balka KR; Cardona Gloria Y; Rao VR; Latz E; Masters SL
J Biol Chem; 2018 Sep; 293(39):15195-15207. PubMed ID: 30076215
[TBL] [Abstract][Full Text] [Related]
17. Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Kleinschek MA; Li C; Liu D; Maclean JK; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Yang R
Bioorg Med Chem Lett; 2015 Nov; 25(22):5384-8. PubMed ID: 26403930
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of N-(3-(4-[
Wang X; Xu W; Miao C; Dong F; Li W; Wang M; Gao M; Zheng QH; Xu Z
Appl Radiat Isot; 2018 Feb; 132():6-12. PubMed ID: 29127936
[TBL] [Abstract][Full Text] [Related]
19. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.
Kato N; Oka M; Murase T; Yoshida M; Sakairi M; Yamashita S; Yasuda Y; Yoshikawa A; Hayashi Y; Makino M; Takeda M; Mirensha Y; Kakigami T
Bioorg Med Chem; 2011 Dec; 19(23):7221-7. PubMed ID: 22019046
[TBL] [Abstract][Full Text] [Related]
20. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
